AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03046030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Description: Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
Study NCT03046030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VGAIT
Description: In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
Study NCT03049839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention_ S
Description: One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
Study NCT03046030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VGAIT control
Description: The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
Study NCT04398550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet
Description: Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
Study NCT04398550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
Study NCT00416455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT
Study NCT02601287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A into detrusor muscle on Day 1
Study NCT03049839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention_ I
Description: One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
Study NCT03049839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention_ C
Description: One year, Intervention program at Community level. People with a FINDRISC less than 12 points
Study NCT00829595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Description: 0.5mL intramuscular, one time
Study NCT00829595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Description: 0.5mL intramuscular, one time
Study NCT00135694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcineurin inhibitor-based immunosuppression
Description: May be cyclosporine, mycophenolate mofetil, or tacrolimus
Study NCT00135694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcineurin inhibitor-based immunosuppression
Description: May be cyclosporine, mycophenolate mofetil, or tacrolimus
Study NCT00135694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver transplant
Description: Occurs at study entry
Study NCT00135694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transplant
Description: Occurs at study entry
Study NCT00135694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: 3-month course of corticosteroids
Study NCT00135694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 3-month course of corticosteroids
Study NCT00135694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunosuppression withdrawal
Description: One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
Study NCT02960802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kidney transplantation
Study NCT03528811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Five points test of Tongji university
Description: In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data.
Study NCT03310749 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
Description: A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
Study NCT03984682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plan
Description: A Joint Crisis Plan will be drafted with the patient and a nurse
Study NCT03720158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Group
Description: Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
Study NCT03720158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo or Control Group
Description: Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
Study NCT03900182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
Study NCT03900182 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
Study NCT02127580 — intervention group
Intervention type: PROCEDURE
Intervention: BAV
Study NCT02127580 — intervention group
Intervention type: PROCEDURE
Intervention: without BAV
Study NCT03341091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-chi group
Description: The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
Study NCT00416455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/CT
Study NCT01868126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution
Study NCT02871388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONECT
Description: 1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
Study NCT02295995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise as an Adjuvant Therapy for Veterans with PTSD
Description: Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
Study NCT04422028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.075 MG
Description: Test Drug
Study NCT04422028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel 0.075 MG
Description: Reference Product
Study NCT03762382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR
Description: TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
Study NCT03762382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV IVR
Description: TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
Study NCT00416455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT
Study NCT00416455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxtran-10
Description: Undergo femoxtran-10 MRI
Study NCT00416455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo femoxtran-10 MRI
Study NCT00416455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic lymphadenectomy
Description: Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
Study NCT01868126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost ophthalmic solution
Study NCT01868126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00416455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node biopsy
Description: Undergo pelvic and abdominal lymph node biopsy
Study NCT02280317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL201
Description: VAL201-001 Sub-cutaneous injection.
Study NCT04192552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAUSE Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure.
Study NCT04192552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASRA Perioperative DOAC Management
Description: Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl >80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk
Study NCT03762382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Description: Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
Study NCT03215329 — intervention group
Intervention type: PROCEDURE
Intervention: abdominal or vascular surgery
Description: Intermediate or high risk abdominal or vascular surgery
Study NCT01636076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149
Description: delivered via Concept1 device
Study NCT01636076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: delivered via Accuhaler®
Study NCT05058066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment
Description: The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
Study NCT05058066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment
Description: The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
Study NCT05058066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early loading
Description: Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
Study NCT02936206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
Study NCT02936206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 14 days of treatment with tamoxifen 20mg orally each day
Study NCT02661789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin 3.6 mg implant
Description: Pharmacologically induced biphasic sex-steroid hormone fluctuation
Study NCT02661789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of saline
Study NCT03581032 — intervention group
Intervention type: DEVICE
Intervention: Active reprogam
Description: Reprogram Changes in AV/PV delays
Study NCT00986817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
Study NCT00986817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
Study NCT02369757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator intervention
Description: peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
Study NCT02409017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin drip
Study NCT03648047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital kinematic biofeedback device
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
Study NCT03648047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Patients will receive conventional face-to-face sessions by a Physical Therapist.
Study NCT03648047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional face-to-face rehabilitation sessions
Description: Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
Study NCT01475812 — intervention group
Intervention type: OTHER
Intervention: Hyperinflation and ADL
Description: Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
Study NCT02874222 — intervention group
Intervention type: OTHER
Intervention: surveys completed by subject
Description: Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
Study NCT00265876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: Taken daily every 4 weeks
Study NCT03422666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide
Study NCT03422666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04471324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS cryo probe
Description: patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
Study NCT03063268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trust-Enhanced Messaging on E-Consent
Description: Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
Study NCT03063268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive features on E-Consent
Description: Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
Study NCT03063268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard E-Consent
Description: Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
Study NCT03063268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard E-Consent
Description: Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
Study NCT04534881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 200 MG
Description: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
Study NCT04534881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
Study NCT01008449 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical staples
Description: Surgical staples will be used once for wound closure.
Study NCT01008449 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Surgical Suture
Description: Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
Study NCT01506011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Study NCT01506011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate/Benazepril HCl
Description: Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
Study NCT04481061 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Electronic Decision Tool
Description: Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
Study NCT01894243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
Study NCT01717326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD
Study NCT00265876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 IV weekly
Study NCT01773850 — intervention group
Intervention type: DEVICE
Intervention: Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner
Description: All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.